tldrdailynews.com logo

AI uncovers the data behind Novo's Parkinson's stem-cell program

1 min read
Source: Endpoints News
AI uncovers the data behind Novo's Parkinson's stem-cell program
Photo: Endpoints News
TL;DR

After Novo Nordisk shuttered its cell-therapy unit, Cellular Intelligence hired neurologist Nuno Mendonça to perform due diligence on Novo’s Parkinson’s stem-cell program. The data trail—drawn from Lund University research and Nature Medicine–published work on dopamine-neuron therapies—appears to have driven the AI-driven assessment that led the firm to pursue Novo’s asset.

Topics:healthbiotech#biotech#bluerock-therapeutics#cellular-intelligence#novo-nordisk#parkinsons-disease#stem-cell-therapy
Share this article
  1. The data that led an AI biotech to pick up Novo's Parkinson's stem cell therapy  Endpoints News
  2. Clinical trial finds stem cell brain transplants feasible for Parkinson's disease  News-Medical
  3. Human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease: a phase 1/2 open-label trial  Nature
  4. New Stem Cell Therapy Shows Promise for Parkinson’s at ISSCR 2026  Bioengineer.org
  5. Data highlight progress toward personalized stem cell therapy for Parkinson's disease  Medical Xpress

Want the full story? Read the original reporting

Read on Endpoints News